Leishmaniasis at the end of the millennium

Pearson, Richard D.; Lareau, Susan M.; Jerônimo, Selma M. B.

doi:10.1007/s11908-999-0057-8

Cited by 10 publications

(6 citation statements)

References 38 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pentavalent antimonial compounds were considered the treatment of choice for decades, but the development of resistance among L. donovani isolates in countries such as India and serious side effects have limited their use in many areas [Berman, 2005; Herwaldt et al, 1992]. Even so, it is still effective and remains standard therapy in many areas of the world, including Brazil [Pearson et al, 1999; Murray et al, 2005]. The recommended dose is 20 mg pentavalent antimony/kg body weight per day given intravenously or intramuscularly.…”

Section: The Challenges Of Treating Leishmaniasismentioning

confidence: 99%

New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas

Dupnik

Nascimento

Rodrigues-Neto

et al. 2011

Drug Development Research

View full text Add to dashboard Cite

Visceral leishmaniasis [VL] represents a major public health problem in many areas of the world. This review focuses on the impact of periurbanization on the epidemiology and treatment of VL, using Brazil as an example. VL continues to be mostly a disease of poverty with impact on families. However, the disease has expanded in Latin America, with foci reported as far south as Argentina. There is an increasing overlap of Leishmania infantum chagasi and HIV infections and other immunosuppressive conditions, resulting in VL emerging as an opportunistic infection. This new setting poses new challenges for VL disease control and patient management.

show abstract

Section: The Challenges Of Treating Leishmaniasismentioning

confidence: 99%

New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas

Dupnik

Nascimento

Rodrigues-Neto

et al. 2011

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…Leishmaniasis is a vector-borne parasitic disease endemic in nearly 100 countries worldwide (8,33). The disease is contracted when an infected female phlebotamine sandfly takes a blood meal, injecting promastigotes into the skin of the host.…”

mentioning

confidence: 99%

“…transform into the amastigote stage to survive and replicate in macrophage phagolysosomes (36). Clinical manifestations of the disease range from localized, self-healing skin lesions to a potentially fatal disease where parasites disseminate to the visceral organs (8,33). Leishmania major causes cutaneous leishmaniasis.…”

mentioning

confidence: 99%

Reduced Pathology following Infection with TransgenicLeishmania majorExpressing Murine CD40 Ligand

et al. 2007

View full text Add to dashboard Cite

Leishmanization is the inoculation of live Leishmania into the host to vaccinate against subsequent infections. This approach has been largely discontinued due to safety concerns. We have previously shown that combining CD40 ligand (CD40L) with Leishmania antigen preferentially induces a type 1 immune response and provides some protection to vaccinated mice (G. Chen, P. A. Darrah, and D. M. Mosser, Infect. Immun. 69:3255-3263, 2001). In the present study, we developed transgenic L. major organisms which express and secrete the extracellular portion of CD40L (L. major CD40LE). We hypothesized that these organisms would be less virulent but more immunogenic than wild-type organisms and therefore be more effective at leishmanization. Transgenic parasites expressing CD40L mRNA and protein were developed. BALB/c mice infected with these parasites developed significantly smaller lesions containing fewer parasites than animals infected with wild-type organisms. Infection of resistant C57BL/6 mice with low doses of transgenic parasites induced a significant amount of protection against subsequent high-dose infection with wild-type organisms. These results demonstrate that transgenic organisms expressing CD40L are less virulent than wild-type organisms while retaining full immunogenicity.

show abstract

“…This is a particularly important factor in endemic regions as observation may be appropriate if the lesion is not located in a cos‐metically sensitive site [2, 3]. Because precise speciation is essential for prognosis and therapy, a sample biopsy should be taken to confirm infection and PCR performed for speciation [4, 5].…”

Section: Discussionmentioning

confidence: 99%

Photodynamic treatment of cutaneous leishmaniasis

Sohl

Kauer

Paasch

et al. 2007

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Leishmaniasis is a widespread arthropod-borne protozoan zoonosis caused by more than 21 Leishmania species. Vectors are sandflies of different genera. The disease is classified into "Old World" versus "New World" leishmaniasis and further subclassified in cutaneous, mucocutaneous and visceral forms. Most therapeutic approaches are not evidence-based. We report a patient with facial cutaneous Leishmania tropica infection which proved to be resistant to various therapeutic regimes. Excellent results were achieved with photodynamic therapy.

show abstract

Leishmaniasis at the end of the millennium

Cited by 10 publications

References 38 publications

New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas

New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas

Reduced Pathology following Infection with TransgenicLeishmania majorExpressing Murine CD40 Ligand

Photodynamic treatment of cutaneous leishmaniasis

Contact Info

Product

Resources

About